Brief: Novonesis Maintains 2024 Outlook

Novozymes A/S

03/05/2024 07:16

May 3 (Reuters) - Novozymes A/S  NSISb.CO :
    * REALIZED 4% ORGANIC SALES GROWTH IN LINE WITH EXPECTATIONS
AND
MAINTAINS 2024 OUTLOOK
    * WE ARE OFF TO A GOOD START IN LINE WITH EXPECTATIONS AND
VERY
WELL ON TRACK TO DELIVER 5-7% ORGANIC SALES GROWTH FOR FULL YEAR
    * OUTLOOK 2024: GROWTH IN FOOD & BEVERAGES IS EXPECTED TO BE
DRIVEN BY BROAD PERFORMANCE ACROSS SUBAREAS
    * OUTLOOK 2024: GROWTH IN HUMAN HEALTH IS EXPECTED TO BE
DRIVEN BY
SALES OF ADVANCED PROTEIN SOLUTIONS TO ANCHOR CUSTOMER AS WELL
AS BY DIETARY SUPPLEMENTS
    * OUTLOOK 2024: HOUSEHOLD CARE IS EXPECTED TO BE DRIVEN BY
INCREASED PENETRATION ACROSS MARKETS
    * OUTLOOK 2024: AGRICULTURE, ENERGY & TECH IS EXPECTED TO BE
DRIVEN BY GROWTH ACROSS ALL SUBAREAS LED BY ENERGY
    * NOVONESIS - Q1 PRO FORMA SALES IN EUR AMOUNTED TO 965.5
MILLION,
AN INCREASE OF 1%
    * Q1 REPORTED SALES IN EUR WERE 853.5 MILLION (Q1 2023: EUR
621.1
MILLION)
    * FOOD & HEALTH BIOSOLUTIONS REALIZED PRO FORMA ORGANIC
SALES
GROWTH OF 3% FOR Q1 2024
    * Q1 PLANETARY HEALTH BIOSOLUTIONS REALIZED PRO FORMA
ORGANIC
SALES GROWTH OF 5% FOR Q1 2024

Source text for Eikon:  ID:nGNE9j437J 
Further company coverage:  NSISb.CO 

 (Gdansk Newsroom)
 ((gdansk.newsroom@thomsonreuters.com; +48 58 772 0920;))